Editas Medicine Tumbles 20% After CEO Steps Down


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Shares of Editas Medicine Inc (NASDAQ:EDIT) tumbled 20 percent Tuesday after the CEO of the genome editing company announced her resignation.

Editas said Katrine Bosley will step down as president, CEO and board member while board member Cynthia Collins will run the company as interim CEO. The search for a permanent CEO is ongoing and Bosley will act as an adviser to ensure a smooth transition.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Why It's Important

It's not yet clear why Bosley is quitting as CEO after the company announced in 2018 the start its first CRISPR trial, which included a $15 million upfront fee from Allergan plc (NYSE:AGN). More recently, the FDA approved the company's IND application and a Phase 1/2 clinical trial will begin patient dosing in the second half of the year.

As interim CEO, Collins will build on Editas' recent successes and "push the pace of innovation and accelerate our achievements" to improve the lives of people who live with serious diseases.

Editas shares traded at $20.65 Tuesday afternoon, down 21 percent on the day.

Related Links:

2 Gene Editing Stocks SunTrust Recommends

Barclays: Editas Medicine On Track To File New Drug App Next Year


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Posted In: NewsManagementMoversTrading IdeasCynthia CollinsFierceBiotechGene EditingKatrine Bosley